More specifically, when Sia acetyl modifying protein, CASD1, is knocked out via CRISPR Cas9 genome editing, lung and colon cancer cells tend to upregulate their activated EGFR expression levels to compensate for the genetic aberration. This evidence concerns the gene EGFR and colonic neoplasm.